Saturday 17 October 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.

790.74 5.60 −0.70%

Follow REGN

Alert me

Market cap: $82.0B
P/E: 18.9×
Fwd P/E: 16.5×
Dividend yield: 0.47%
F-score: 5/9
Altman Z: 7.49
Beneish M: −2.53
Dividend safety: 77/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 11.86

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	—	1	3	1	1	1	—	1	2	2	1

Insider Ownership 3.63%

Capital & Financial Ratios $m

Market Cap 81,990.00

Revenue 15,534.70

Net Income 4,328.70

Free Cash Flow 3,575.20

Net Debt (6,008.00)

Current Ratio 3.34

Debt/Equity 0.06

P/E ratio 18.87

Fwd P/E 16.50

P/S ratio 5.23

P/B ratio 2.56

Past 5Y EPS Growth 6.33%

This Y EPS Growth 32.13%

Next Y EPS Growth 6.85%

Next Y revenue growth 20.31%

Next 5Y EPS Growth 16.28%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 48.29%

10-year low 10-year high

P/S against its own 10 years 21.16%

10-year low 10-year high

P/B against its own 10 years 13.20%

10-year low 10-year high

EV/Sales against its own 10 years 20.46%

10-year low 10-year high

EV/FCF against its own 10 years 38.48%

10-year low 10-year high

Dividends

Payout Ratio 0.09

Annual Dividend Rate 3.70

Annual Dividend Yield 0.47%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	3.90	0.94 0.94 0.94
2025	3.52	0.88 0.88 0.88 0.88
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	10,845	9,013	8,605	7,995
Receivables	5,667	6,212	5,741	6,565
Inventory	2,581	3,087	3,201	3,084
Other	—	—	—	—
	19,479	18,661	18,022	18,446

	2023	2024	2025	Q'26
Payables	607	790	939	1,159
ST’ Debt	—	—	—	—
Other	2,358	2,527	2,876	—
	3,423	3,944	4,368	5,531

Compound Annual Growth %

	10y	5y	3y
Sales	13.33%	11.04%	5.62%
Cash Flow	14.10%	13.72%	(0.24%)
Earnings	21.62%	5.10%	1.26%
Book Value	23.94%	23.17%	11.31%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3,605	4,291	—	—	—
’25	3,029	3,676	3,754	3,884	14,343
’24	3,145	3,547	3,721	3,789	14,202
’23	3,162	3,158	3,363	3,434	13,117
’22	2,965	2,857	2,936	3,414	12,173
’21	2,529	5,139	3,453	4,952	16,072
’20	1,828	1,952	2,294	2,423	8,497

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,079	813	—	—	—
’25	1,045	1,144	1,619	1,171	4,979
’24	1,513	354	1,291	1,263	4,421
’23	1,368	1,022	1,114	1,090	4,594
’22	2,102	564	629	1,720	5,015
’21	669	627	3,414	2,373	7,081
’20	698	943	(254)	1,231	2,618

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	799	522	—	—	—
’25	774	738	1,374	880	3,765
’24	1,351	163	1,049	996	3,559
’23	1,089	889	914	776	3,668
’22	1,960	411	(440)	1,468	3,398
’21	553	478	3,280	2,218	6,529
’20	528	814	(407)	1,070	2,004

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	6.75	12.23	—	—	—
’25	7.27	12.81	13.62	7.86	41.48
’24	6.27	12.41	11.54	8.06	38.34
’23	7.17	8.50	8.89	10.19	34.77
’22	8.61	7.47	11.66	10.50	38.22
’21	10.09	27.97	14.33	19.69	71.97
’20	5.43	7.61	7.39	10.24	30.52

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	325.35	340.09	281.89	271.37	328.13	441.00	538.01	668.00	693.00	476.49	Analyst estimates 2026–2028 Powerpack
	High	532.91	543.55	416.49	442.00	664.64	686.62	779.00	899.86	1,211.20	792.77
People
People	Employees	5,400	6,200	7,400	8,100	9,123	10,368	11,851	13,450	15,106	15,410
	Revenue/emp, $m	0.90	0.95	0.70	0.81	0.93	1.55	1.03	0.98	0.94	0.93
Income, $m
Income, $m	Revenue	4,860	5,872	5,146	6,558	8,497	16,072	12,173	13,117	14,202	14,343
	Gross margin, %	93.83	93.24	91.89	88.33	86.82	84.83	87.18	86.16	86.13	85.35
	EBT	1,330	2,079	2,554	2,429	3,810	9,326	4,859	4,199	4,780	5,231
	EBT margin, %	27.36	35.40	49.62	37.04	44.84	58.03	39.91	32.01	33.66	36.47
	Net income	896	1,199	2,444	2,116	3,513	8,075	4,338	3,954	4,413	4,505
	Depreciation	105	146	148	210	236	286	341	421	483	544
Per share, $
Per share, $	Revenue	46.42	55.24	47.69	60.05	78.97	152.05	113.66	122.94	131.62	137.12
	Earnings	8.55	11.27	22.65	19.38	32.65	76.40	40.51	37.05	40.90	43.07
	Cash flow	14.19	12.30	20.34	22.25	24.33	66.99	46.82	43.06	40.97	47.60
	Capex	(4.89)	(2.56)	(3.55)	(3.93)	(5.71)	(5.22)	(15.10)	(8.68)	(7.98)	(11.60)
	Free cash flow	9.30	9.73	16.79	18.32	18.62	61.77	31.73	34.37	32.98	36.00
	Book value	42.50	57.80	81.16	101.55	102.47	177.57	211.62	243.42	272.04	298.82
	Shares, m	105	106	108	109	108	106	107	107	108	105
Valuation, ×
Valuation, ×	P/E	45.15	33.92	16.50	19.38	14.75	8.26	17.78	24.43	17.42	17.90
	P/S	8.18	6.93	7.83	6.25	6.12	4.15	6.34	7.36	5.41	5.63
	P/B	8.94	6.62	4.60	3.70	4.71	3.56	3.40	3.72	2.62	2.58
	EV/Sales	8.04	6.81	7.42	5.87	6.19	4.02	6.05	6.86	5.07	5.32
	EV/FCF	40.11	38.63	21.08	19.25	26.25	9.88	21.67	24.52	20.25	20.27
Cash, $m
Cash, $m	Operating cash flow	1,486	1,307	2,195	2,430	2,618	7,081	5,015	4,594	4,421	4,979
	Capex	(512)	(273)	(383)	(430)	(615)	(552)	(1,617)	(926)	(861)	(1,214)
	Free cash flow	974	1,035	1,812	2,000	2,004	6,529	3,398	3,668	3,559	3,765
Balance, $m
Balance, $m	Working capital	1,939	3,200	5,005	5,593	7,082	10,082	12,743	16,056	14,717	13,654
	Total debt	352	704	709	714	2,696	1,980	2,701	2,703	2,704	2,706
	Net debt	(687)	(706)	(2,101)	(2,500)	(891)	(3,715)	(5,041)	(8,142)	(6,308)	(5,899)
	Shareholders’ equity	4,449	6,144	8,757	11,090	11,025	18,769	22,664	25,973	29,354	31,257
Returns, %
Returns, %	ROA	14.23	15.23	23.85	15.94	21.98	37.91	15.88	12.69	12.46	11.50
	ROIC	22.11	23.90	23.80	16.08	22.06	37.14	16.81	14.19	10.82	8.82
	ROE	22.10	22.63	32.81	21.32	31.77	54.21	20.94	16.26	15.95	14.87

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VRTX Vertex Pharmaceuticals Incorporated	$129.0B	28.8×	25.5×	+12.45% (above 0%: growing)	+7.96% (above 0%: growing)	+9.25% (above 0%: growing)	85.33%	37.40%	Compare
MRNA Moderna, Inc.	$94.4B	— (loss-making)	— (loss-making)	+2.11% (above 0%: growing)	n/m	+38.94% (above 0%: growing)	35.86%	(562.07%)	Compare
REGN Regeneron Pharmaceuticals, Inc.	$82.0B	18.9×	16.5×	+16.73% (above 0%: growing)	−4.68% (below 0%: shrinking)	−29.26% (below 0%: shrinking)	86.56%	30.15%
ARGX argenex SE	$53.2B	29.6×	32.4×	+59.46% (above 0%: growing)	+88.56% (above 0%: growing)	+537.51% (above 0%: growing)	90.60%	32.04%	Compare
RVMD Revolution Medicines, Inc.	$40.6B	— (loss-making)	— (loss-making)	−77.89% (below 0%: shrinking)	n/m	−69.98% (below 0%: shrinking)	100.00%	0.00%	Compare
ONC BeOne Medicines Ltd. - Sponsored ADR	$39.0B	62.6×	40.2×	+29.63% (above 0%: growing)	+143.68% (above 0%: growing)	+117.92% (above 0%: growing)	89.76%	19.06%	Compare
RPRX Royalty Pharma PLC	$34.3B	42.3×	21.9×	+16.50% (above 0%: growing)	−40.00% (below 0%: shrinking)	+31.57% (above 0%: growing)	100.00%	19.75%	Compare
ALNY Alnylam Pharmaceuticals, Inc.	$31.3B	39.5×	39.6×	+66.86% (above 0%: growing)	n/m	+152.82% (above 0%: growing)	76.88%	17.93%	Compare
ROIV Roivant Sciences Ltd.	$24.6B	— (loss-making)	— (loss-making)	−33.55% (below 0%: shrinking)	n/m	−29.99% (below 0%: shrinking)	80.31%	(25,380.93%)	Compare
Median of peers	$39.8B	39.5×	32.4×	+14.48%	+48.26%	+35.26%	87.55%	18.50%

All 614 Biotechnology stocks →

Regeneron Pharmaceuticals, Inc. (REGN) key facts

Strength: Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
Strength: Net income was $4.5 billion, or $43.07 per share (basic), a net margin of 31.4%.
Regeneron Pharmaceuticals, Inc. (REGN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, REGN traded at $790.74, a market capitalization of $82.0 billion.
At that price the stock trades at 18.9× trailing-twelve-month earnings and 5.2× sales; its P/E is higher than 48% of its own readings over the past ten years.
Regeneron Pharmaceuticals, Inc. pays an annual dividend of $3.70 per share, a yield of 0.47%, with a payout ratio of 9.14%.
Return on equity was 14.9% and debt-to-equity 0.06.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 7.49 (safe zone) for fiscal 2025.